

## Correction: *Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy*

Simister PC, Border EC, Vieira JF, *et al.* Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy. *J Immunother Cancer* 2022;10:e004600. doi: 10.1136/jitc-2022-004600.

This article has been corrected since it was first published online. There was a misidentification of the engineered residue; instead of bCDR2 residue E53 engineered it should have been bCDR1 E31. This has now been corrected throughout the article.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*J Immunother Cancer* 2022;10:e004600corr1. doi:10.1136/jitc-2022-004600corr1

